title: Unrelated cord blood transplantation can restore hematologic and immunologic functions in patients with Chediak-Higashi syndrome.
abstract: CHS is a rare hereditary fatal disease, if not treated. APs occur in 85% of patients and are usually the main cause of mortality, and HSCT from HLA-matched related and unrelated donors is the only effective treatment for CHS and prevents recurrences of APs. We reviewed the records of three patients with CHS who underwent UCBT at KHCC. Records were examined for clinical features at the time of UCBT, conditioning regimens, morbidities, and outcomes. Conditioning comprised BU, cyclophosphamide, horse ATG, and etoposide. All patients tolerated the conditioning well. Two patients are alive, one with mixed and the other with full donor chimerism; hematologic and immunologic defects of CHS have been corrected in both patients. They show no evidence of recurrences of APs and have normal growth and development. In patients with CHS who lack HLA-matched related and unrelated donors, UCBT is a suitable alternative source of stem cells to restore immunologic and hematologic functions and prevent AP relapses, even in mixed chimeric states. Long follow-up and close monitoring are essential to evaluate the long-term benefits of using UCBT in patients with CHS.
authors: Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan. rrihani@khcc.jo
authors: Rawad
authors: R
authors: Rihani
authors: Maha
authors: M
authors: Barbar
authors: Nesreen
authors: N
authors: Faqih
authors: Hadeel
authors: H
authors: Halalsheh
authors: Ayad Ahmad
authors: AA
authors: Hussein
authors: Abdul Hadi
authors: AH
authors: Al-Zaben
authors: Fawzi Abdel
authors: FA
authors: Rahman
authors: Mahmoud
authors: M
authors: Sarhan
mesh_terms: D002609:Chediak-Higashi Syndrome / Q000097:blood / Q000276:immunology / Q000601:surgery*; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome